Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - May 2014

ADC Summit 2014 London

19 May 2014 - 20 May 2014 - London, UK

Bookmark and Share

Making your smart bomb smarter - creating innovative antibody-drug conjugates

SMi’s 3rd annual Antibody Drug Conjugates Summit comes at the perfect time to focus on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, bringing together key industry experts from academia, pharma and biotech companies.

Join us this May in London to hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.


  • Hear cutting edge presentations and key case studies from leading ADCs experts on key topics such as nano-delivery systems, advancing preclinical development to accelerate ADCs into the clinic, next generation ADCs and manufacturing challenges
  • Network and learn from industry and academic opinion leaders including Photobiotics, Medlmmune, Spirogen, Synthon plus many more…
  • Learn about latest developments pertaining to the components of ADCs (payload, antibody and linker)
  • Join the debate in our round table session to discuss creative strategies in making the “smart bomb” more intelligent when building your oncology arsenal


  • Dr Mahendra Deonarain, Chief Scientific Officer, Photobiotics
  • Dr Adeela Kamal, Associate Director, R&D, Oncology Research, MedImmune
  • Philip Howard, PhD, Chief Scientific Officer, Spirogen Limited
  • Dr Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
  • Dr Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, Synthon
  • Dr Erica Hong, Scientist, ImmunoGen
  • Dr Hagop Youssoufian, Executive Vice President of R&D, Progenics
  • Dr Pamela Trail, Vice President Oncology, Regeneron

This 2 day networking event will invite in depth discussion of key drivers impacting ADCs, providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. 

To download a brochure and to secure your attendance visit 

Alternatively for further information contact Fateja Begum on +44 (0)20 7827 6184 or email 

Further information
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos